Our Mission

Our mission is to transform the treatment of Acute Myeloid Leukemia by eliminating chemotherapy-resistant and relapse-driving leukemic stem cells and stem-like progenitors. We achieve this through 3rd-generation conditional bispecific T-cell engagers, with built-in checkpoint inhibition, engineered for the immune evasion mechanisms of leukemic stem cells.